Mylan LLC
Pharmaceutical & medical device company payment data from CMS Open Payments.
Total Payments
$4.6M
Doctors Paid
284
Transactions
1,599
2024 Total
$588,768
Payment Breakdown by Category
Research$3.4M (73.7%)
Consulting$406,547 (8.8%)
Travel$202,678 (4.4%)
Food & Beverage$16,502 (0.4%)
Payments by Nature
| Nature of Payment | Amount | Transactions | Share |
|---|---|---|---|
| Unspecified | $3.4M | 266 | 73.7% |
| Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | $585,266 | 240 | 12.6% |
| Consulting Fee | $406,547 | 102 | 8.8% |
| Travel and Lodging | $202,678 | 285 | 4.4% |
| Food and Beverage | $16,502 | 700 | 0.4% |
| Space rental or facility fees (teaching hospital only) | $10,000 | 1 | 0.2% |
| Education | $1,995 | 5 | 0.0% |
Payments by Type
Research
$3.4M
266 transactions
General
$1.2M
1,333 transactions
Research Studies & Clinical Trials
| Study Name | Total Paid | Doctors | Records |
|---|---|---|---|
| A PHASE 3, MULTICENTER, OPEN-LABEL, SINGLE ARM STUDY OF MR-100A-01 IN WOMEN OF CHILDBEARING POTENTIAL TO EVALUATE CONTRACEPTIVE EFFICACY AND SAFETY | $948,409 | 0 | 102 |
| Retrospective Patient Level Data Collection for Subjects in FondaKIDS III Study | $800,000 | 0 | 2 |
| MELO-TFZ-2002 | $527,324 | 0 | 3 |
| AED Pregnancy Registry | $340,000 | 0 | 4 |
| RADARS | $249,201 | 0 | 8 |
| 11932904 | $176,800 | 0 | 3 |
| PRECISION Trial Biomarker Sub study | $97,061 | 0 | 1 |
| A Multi Center, Randomized, Double-Masked, Active-Controlled, Comparative Clinical Study to Evaluate the Efficacy and Safety of MYL-1701P and Eylea in Subjects With Diabetic Macular Edema | $76,007 | 1 | 25 |
| MYL-1701P | $54,923 | 3 | 11 |
| NCT03502070 | $47,847 | 0 | 27 |
| MELO-TFZ-2001 | $44,237 | 0 | 3 |
| MELO-TFZ-2003 | $38,758 | 0 | 3 |
| Mycophenolate Pregnancy Exposure Registry | $6,750 | 4 | 8 |
| A Randomized, Multicenter, Open-Label, Parallel-Group Clinical Study Comparing the Safety and Efficacy of MYL-1601D With NovoLog in Type 1 Diabetes Mellitus Patients; Extension Study to Assess Safety and Efficacy of Mylan's Insulin Glargine and Lantus in Type 1 Diabetes Mellitus (T1DM) Patients | $5,525 | 1 | 1 |
| Antiretroviral Pregnancy Registry (APR) | $3,629 | 3 | 42 |
| REV-3001-A RANDOMIZED, DOUBLE BLIND, PLACEBO-CONTROLLED, PARALLEL GROUP STUDY OF NEBULIZED REVEFENACIN INHALATION SOLUTION IN CHINESE SUBJECTS WITH MODERATE TO VERY SEVERE CHRONIC OBSTRUCTIVE PULMONARY DISEASE (COPD). | $3,589 | 0 | 1 |
| Antiretroviral Pregnancy Registry (APR): Multi-sponsor Registry to Detect Any Major Teratogenic Effect Involving Any of the Registry Drugs When Administered to Pregnant Women. (APR) | $1,100 | 5 | 21 |
| Evaluating the Abuse Potential of NEURONTIN When Taken Orally in Healthy Non-drug Dependent Participants With Sedative Drug Abuse Experience - A9451180 | $295.00 | 0 | 1 |
Payments by Medical Specialty
Top Paid Doctors
| Doctor | Specialty | Location | Total | 2024 |
|---|---|---|---|---|
| Dr. Sripal Bangalore, M.d., M.h.a, M.D., M.H.A | Cardiovascular Disease | New York, NY | $167,902 | $0 |
| Marc Berger, M.d, M.D | Internal Medicine | New York, NY | $88,837 | $0 |
| Rakesh Jain, Md, MD | Psychiatry | Lake Jackson, TX | $48,563 | $0 |
| Christoph Correll, Md, MD | Psychiatry | Glen Oaks, NY | $45,092 | $0 |
| Dr. Hope Rugo, Md, MD | Internal Medicine | San Francisco, CA | $41,953 | $0 |
| Susan Bressler, M.d, M.D | Ophthalmology | Lutherville, MD | $35,465 | $0 |
| Jeffrey Cohen, Md, MD | Neurology | Cleveland, OH | $29,934 | $0 |
| Jill Ohar, Md, MD | Pulmonary Disease | Winston Salem, NC | $22,690 | $0 |
| John Mulhall, Md, MD | Urology | New York, NY | $20,719 | $0 |
| William White, Md, MD | Hypertension Specialist | Farmington, CT | $20,550 | $0 |
| Aaron Milstone, Md, MD | Pulmonary Disease | Franklin, TN | $18,892 | $0 |
| Antonio Anzueto, Md, MD | Pulmonary Disease | San Antonio, TX | $18,573 | $0 |
| Lori Goldstein, M.d, M.D | Specialist | Philadelphia, PA | $18,400 | $0 |
| Rodica Busui, Md, Phd, MD, PHD | Endocrinology, Diabetes & Metabolism | Portland, OR | $18,351 | $0 |
| Robert Rosenson, Md, MD | Cardiovascular Disease | New York, NY | $15,255 | $0 |
| Donald Tashkin, Md, MD | Pulmonary Disease | Los Angeles, CA | $14,000 | $0 |
| Mr. Manuel Suarez Barcelo, Md, MD | Internal Medicine | North Miami, FL | $12,056 | $0 |
| Dr. William Berger, M.d, M.D | Allergy | Mission Viejo, CA | $11,288 | $0 |
| David Sheehan, Md, MD | Psychiatry | Tampa, FL | $11,070 | $0 |
| Dr. James Donohue, Md, MD | Pulmonary Disease | Chapel Hill, NC | $10,780 | $0 |
| Gary Ferguson, M.d, M.D | Internal Medicine | Livonia, MI | $10,447 | $0 |
| Dr. Michael Thase, Md, MD | Psychiatry | Philadelphia, PA | $10,405 | $0 |
| Dr. Donald Mahler, M.d, M.D | Pulmonary Disease | Lebanon, NH | $10,203 | $0 |
| Phillip Lieberman, Md, MD | Allergy & Immunology | Memphis, TN | $10,063 | $0 |
| Charles Nemeroff, Md Phd, MD PHD | Psychiatry | Austin, TX | $10,061 | $0 |
Ad
Top Products
- ARIXTRA $800,000
- Meloxicam $610,320
Associated Products (7)
- ARIXTRA $800,000
- Levothyroxine Sodium $221,000
- Wixela Inhub $108,832
- Fentanyl $97,728
- EFFEXOR $28,879
- CLOZAPINE $25,298
- NORVASC $13,332
Payment Categories
- Food & Beverage $16,502
- Consulting $406,547
- Travel & Lodging $202,678
- Research $3.4M
About Mylan LLC
Mylan LLC has made $4.6M in payments to 284 healthcare providers, recorded across 1,599 transactions in the CMS Open Payments database. In 2024, the company paid $588,768. The top product by payment volume is ARIXTRA ($800,000).
Payments were distributed across 55 medical specialties. The top specialty by payment amount is Cardiovascular Disease ($199,344 to 5 doctors).
Payment categories include: Food & Beverage ($16,502), Consulting ($406,547), Research ($3.4M), Travel & Lodging ($202,678).
Mylan LLC is associated with 7 products in the CMS Open Payments database, including ARIXTRA, Levothyroxine Sodium, and Wixela Inhub.